$3.55 Billion is the total value of PFM Health Sciences, LP's 75 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | New | ALLERGAN PLC | $165,475,000 | – | 608,789 | +100.0% | 4.66% | – |
| GILD | New | GILEAD SCIENCES INC | $110,559,000 | – | 1,125,974 | +100.0% | 3.11% | – |
| LLY | New | LILLY ELI & CO | $92,573,000 | – | 1,106,139 | +100.0% | 2.60% | – |
| HD | New | HOME DEPOT INC | $60,787,000 | – | 526,343 | +100.0% | 1.71% | – |
| PCLN | New | PRICELINE GRP INC | $56,745,000 | – | 45,878 | +100.0% | 1.60% | – |
| FBHS | New | FORTUNE BRANDS HOME & SEC IN | $48,331,000 | – | 1,018,137 | +100.0% | 1.36% | – |
| MA | New | MASTERCARD INCcl a | $45,068,000 | – | 500,093 | +100.0% | 1.27% | – |
| GOOGL | New | GOOGLE INCcl a | $42,330,000 | – | 66,310 | +100.0% | 1.19% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $31,992,000 | – | 758,816 | +100.0% | 0.90% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $25,222,000 | – | 996,112 | +100.0% | 0.71% | – |
| PEN | New | PENUMBRA INC | $15,289,000 | – | 381,270 | +100.0% | 0.43% | – |
| ZLTQ | New | ZELTIQ AESTHETICS INC | $14,275,000 | – | 445,686 | +100.0% | 0.40% | – |
| BCR | New | BARD C R INC | $14,079,000 | – | 75,570 | +100.0% | 0.40% | – |
| TXT | New | TEXTRON INC | $13,452,000 | – | 357,388 | +100.0% | 0.38% | – |
| DBVT | New | DBV TECHNOLOGIES S Asponsored adr | $9,750,000 | – | 273,965 | +100.0% | 0.27% | – |
| New | CLOVIS ONCOLOGY INCnote 2.500% 9/1 | $8,045,000 | – | 4,805,000 | +100.0% | 0.23% | – | |
| New | ALLERGAN PLCcall | $2,518,000 | – | 314,700 | +100.0% | 0.07% | – | |
| RGNX | New | REGENXBIO INC | $2,364,000 | – | 107,305 | +100.0% | 0.07% | – |
| New | MERCK & CO INC NEWput | $1,750,000 | – | 1,301,300 | +100.0% | 0.05% | – | |
| New | PTC THERAPEUTICS INCcall | $1,306,000 | – | 428,200 | +100.0% | 0.04% | – | |
| New | TEVA PHARMACEUTICAL INDS LTDcall | $1,009,000 | – | 2,713,000 | +100.0% | 0.03% | – | |
| New | BRISTOL MYERS SQUIBB COcall | $419,000 | – | 2,537,100 | +100.0% | 0.01% | – | |
| KERX | New | KERYX BIOPHARMACEUTICALS INC | $344,000 | – | 97,687 | +100.0% | 0.01% | – |
| TDOC | New | TELADOC INC | $305,000 | – | 13,670 | +100.0% | 0.01% | – |
| New | PFIZER INCcall | $265,000 | – | 2,207,400 | +100.0% | 0.01% | – | |
| New | ROCKWELL AUTOMATION INCcall | $87,000 | – | 388,600 | +100.0% | 0.00% | – | |
| New | MCKESSON CORPcall | $26,000 | – | 343,100 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.